Chiesi USA Sales reached €258 million, representing
overall growth of 2.6%.
2017 was a year of challenges and, ultimately, a year of success for Chiesi USA. Multiple product approvals were achieved. These included approval for the completed tech transfer for Retavase® and two new strengths for Pertzye®, 4,000 and 24,000. 2017 was also the first full year of our Corporate Social Responsibility program, Chiesi in the Community.
General Manager Chiesi USA, Inc.
• The main achievement for Chiesi USA was exceeded budget on both revenue and profitability, after adjusting for the generic competition for ZyfloCR.
• Chiesi in the Community was also a major success. The program had a positive impact beyond expectations on affiliate awareness, positive impact in the local community and company culture.